<DOC>
	<DOC>NCT00558493</DOC>
	<brief_summary>A multi-center and open study to compare the safety and effectiveness of switching treatment from lamivudine to clevudine for 24 weeks.</brief_summary>
	<brief_title>Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBV DNA &gt; 2,000 copies/mL at screening Patients who have compensated liver disease (ChildPugh score =&lt;6) Patients without LMV resistant mutation by RFMP assay Patients who have NOT experienced viral breakthrough at consecutive two measurements (at least one month apart) during lamivudine monotherapy Patients who can submit the written consent and comply with the claims postulated of this clinical trial Currently receiving antiviral except LMV or corticosteroid therapy Patients that previously received antiviral treatment for hepatitis B other than lamivudine in the proceeding 12 months Previous treatment with interferon or other immunomodulatory therapies must have ended at least 6 months preceding the study screening Treatment with nephrotoxic drugs, competitors of renal excretion, and/or hepatotoxic drugs within 2 months before study screening or during the study period Patients who is coinfected with HCV, HDV or HIV Serious concurrent medical conditions Prior organ transplantation Patient has creatinine clearance less than 60mL/min as estimated by the following formula: [(140age in years) (body weight [kg])] / [(72) (serum creatinine] [mg/dL])[Note: multiply estimates by 0.85 for women]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>